Orforglipron (OriYo) 0.8–17.2mg Tablets | Bangladesh Generic Oral GLP-1 | GLT

Generic Information: OriYo (Bangladesh)

Generic name: orforglipron. Brand name: OriYo. Manufacturer: National Drug Co., Ltd. Origin: Bangladesh. Dosage form: oral film-coated tablets, 30 tablets per box. Class: GLP-1 receptor agonist — an oral, non-peptide, small-molecule agonist of the glucagon-like peptide-1 receptor indicated for weight management.

Orforglipron was discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. Lilly's originator brand Foundayo received US FDA approval in April 2026 as the first oral non-peptide GLP-1 receptor agonist for chronic weight management. Bangladesh has become a major source of generic orforglipron, and OriYo is one of the locally produced versions following the same six-step titration schedule as the originator.

What Is OriYo?

OriYo is a once-daily oral tablet that supports long-term weight loss in adults with obesity, or in adults who are overweight and carry at least one weight-related condition such as type 2 diabetes, high blood pressure, or abnormal blood lipids. It is designed to be used together with a reduced-calorie diet and regular physical activity.

The defining convenience of orforglipron is that it is a small molecule taken by mouth, without the fasting and water restrictions that apply to peptide-based oral GLP-1 drugs. That lowers the barrier for patients who want the benefit of a GLP-1 agonist but prefer a simple daily pill.

How Does OriYo Work?

OriYo activates the glucagon-like peptide-1 (GLP-1) receptor, a target found in the appetite-regulating regions of the brain. This activation reduces appetite and calorie intake and slows gastric emptying so that fullness lasts longer. Over weeks of treatment, and alongside diet and exercise, this translates into sustained weight reduction.

Because orforglipron is a non-peptide small molecule rather than a biologic, it is manufactured by conventional chemical synthesis. That supports scalable production and is a key reason generic oral GLP-1 options like OriYo can be offered at a much lower cost than injectable originator products.

Indications

• Long-term weight management in adults with obesity (BMI ≥ 30 kg/m²)
• Long-term weight management in overweight adults (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity
• Combined with a reduced-calorie diet and increased physical activity

Dosage

OriYo is titrated upward to minimize gastrointestinal discomfort. Begin at 0.8 mg once daily for at least 30 days, then step up to 2.5 mg once daily for at least another 30 days, and then to 5.5 mg once daily. After that, the dose may be increased every 30 days or more through 9 mg and 14.5 mg, up to a maximum of 17.2 mg once daily, depending on tolerability and response.

Take one tablet daily by swallowing it whole — do not split, crush, or chew. It may be taken with or without food, at any time of day.

Side Effects

Gastrointestinal effects are the most common, especially while the dose is being increased: nausea, diarrhea, constipation, vomiting, indigestion, abdominal pain, bloating, and fatigue. These are usually mild to moderate and settle with continued use. Serious reactions that require prompt medical attention include acute pancreatitis, severe or persistent gastrointestinal symptoms, dehydration-related kidney problems, and allergic reactions.

OriYo must not be used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2 syndrome.

Storage

Keep OriYo tablets at room temperature (20°C to 25°C) in the original bottle and carton, away from light and moisture, and out of reach of children. Short temperature excursions between 15°C and 30°C are acceptable.

Why Choose the GLT?

Bangladesh is one of the world's most established markets for affordable generic pharmaceuticals, and OriYo benefits from that manufacturing base: it delivers the same active ingredient and titration schedule as the originator at a fraction of the reference-brand price. For buyers who want an oral GLP-1 weight-management option without the originator's premium, OriYo is a cost-effective route.

GLT sources OriYo directly through verified channels and supplies complete export documentation, giving licensed buyers and individual patients a reliable, traceable supply.

How to Order

GLT supplies OriYo (orforglipron) internationally to licensed buyers and individual patients. For pricing and availability on any of the six strengths, contact us on WhatsApp +86 15234153837 or email [email protected]. Shipments include full documentation and batch traceability, with ambient shipping for oral tablets.

FAQ

Is OriYo a generic of Foundayo? Yes. OriYo contains orforglipron, the same active ingredient as Eli Lilly's Foundayo. It is a Bangladesh-made generic that follows the same six-dose titration schedule, offered at a lower price.

What strengths are available? OriYo comes in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg, each in a 30-tablet box. Treatment starts at 0.8 mg and titrates upward over time.

Do I need to take OriYo on an empty stomach? No. Orforglipron can be taken with or without food and has no water restriction, unlike oral semaglutide.

How do I order orforglipron generic from Bangladesh? GLT supplies the Bangladesh-made OriYo worldwide. Reach us on WhatsApp or email for a quotation and availability.